Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021)

Capricor Therapeutics' (CAPR) quarterly Notes Payables came in at $282691.0 in Q1 2021, up 14.59% quarter-over-quarter from $246689.0 in Q4 2020.

Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021) Analysis & Trends

Capricor Therapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $282691.0 for Q1 2021.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $282691.0 in Q1 2021; TTM through Mar 2021 was $282691.0, a N/A change from a year earlier, with the FY2020 full-year figure at $246689.0, changed N/A from the prior year.
  • Notes Payables rose to $282691.0 in Q1 2021 per CAPR's latest filing, from $246689.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $282691.0 in Q1 2021 and bottomed at $139927.0 in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Capricor Therapeutics 1.12 Bn 1.12 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2021 282,691.00
Dec 31, 2020 246,689.00
Sep 30, 2020 193,241.00
Jun 30, 2020 139,927.00
Sep 30, 2013 326,796.00
Jun 30, 2013 258,514.00
Mar 31, 2013 190,974.00